EE681 Economic Impact of Fixed-Treatment Duration for Chronic Lymphocytic Leukemia: Budget-Impact Analysis of Venetoclax Plus Obinutuzumab for First Line Treatment of Unfit Patients in France
Dec 1, 2023, 00:00 AM
10.1016/j.jval.2023.09.946
https://www.valueinhealthjournal.com/article/S1098-3015(23)04076-7/fulltext
Section Title :
Section Order :
10439
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)04076-7&doi=10.1016/j.jval.2023.09.946